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Fucose-Modified Thermoresponsive Poly(2-Hydroxypropyl 
Methacrylate) Nanoparticles for Controlled Doxorubicin Release 
from an Injectable Depot 
Huayang Yu, a Jason V. Rowley, a David C. Green a and Paul D. Thornton*a 
The modification of poly(2-hydroxypropyl methacrylate) with a single fucose group per polymer chain enabled 
macromolecular self-assembly, and the formation of thermoresponsive nanoparticles. In addition, poly(2-hydroxypropyl 
methacrylate)200 formed a self-healing material that may act as an injectable vehicle and depot for poly(2-hydroxypropyl 
methacrylate) nanoparticle delivery and localisation at a particular site. In combination, the injectable depot permits the 
controlled release of doxorubicin from the fucose presenting nanoparticles that it contains following injection. Such 
thermoresponsive materials are highly promising candidates for the treatment of diseases that may be remedied by 
exploiting targeted fucose-cell binding, such as pancreatic cancer.
Introduction 
Effective cancer treatment in the absence of extremely intrusive 
side-effects remains a key challenge in contemporary medicine.1 
Providing a remedy that destroys cancer cells, whilst leaving healthy 
cells relatively unaffected must be realised for this challenge to be 
overcome.2 Encapsulating a toxic anti-cancer drug within a shielding 
polymeric carrier protects the drug from interacting with cells, thus 
preventing the damage of non-cancerous cells, and the aggressive 
side-effects that are associated with this occurring during 
chemotherapy.3-5 Extensive drug loading into polymeric 
nanoparticles, and a mechanism for the programmed release of the 
drug from the nanoparticles, are essential features of effective 
treatments.6-10 Additionally, next-generation drug delivery vehicles 
must present cell-binding groups that enable extensive therapeutic 
interaction with target cells only.11-13  
    Fucose plays a key role in mammalian development, immunity and 
cancer metastasis.14 Increased expression of fucosyltransferases is 
associated with pancreatic cancer, whereby enzymes accelerate 
malignant transformation through the fucosylation of sialylated 
precursors, and pancreatic cancer cells display enhanced fucose 
uptake. Pancreatic cancer is an extremely aggressive cancer with a 
dismal survival rate; it is estimated that the 5-year survival rate is 5% 
owing to its aggressiveness, and a lack of effective therapies.15 
Currently, patients that undergo treatment with the chemotherapy 
drug Gemcitabine (Gemzar®) have a median survival time reported 
to be only 5.7 months.16 A plausible explanation for this abysmal 
inefficiency is the extremely ineffective delivery of anticancer drugs 
to the tumour site. There is enormous demand for the creation of 
fucose-presenting nanoparticles to be deployed as increasingly 
advanced drug delivery systems for the treatment of pancreatic 
cancer. 
    Poly(2-hydroxypropyl methacrylate) (PHPMA) is non-toxic and 
biocompatible.17-18 PHPMA-containing block copolymers can be 
readily formed by reversible addition-fragmentation chain-transfer 
(RAFT) aqueous dispersion polymerisation.19 Such polymers have 
been reported to self-assemble into a plethora of arrangements 
dependent on their macromolecular configuration, and the 
environment in which they are maintained. For instance, 
poly(glycidyl methacrylate)-b-PHPMA may be manipulated to form 
spheres, worms or vesicles dependent on the composition of the 
block copolymer, and the temperature of the aqueous solution in 
which the polymer is dispersed.20 PHPMA, and PHPMA-based 
materials have been applied to the thermally-triggered release of 
drug molecules,21 and controlled release applications.22 
     Implantable polymer-based materials for drug and cell delivery 
have attracted significant recent attention.23-27 Such materials may 
facilitate the immobilisation of drug-loaded nanoparticles at the 
target site, ensuring extensive drug release at diseased areas, and 
minimal drug release to healthy tissue. This enhances the efficacy of 
the treatment, reducing the side-affects that are caused by drug 
interaction with non-target, healthy cells. An implantable depot that 
enables the controlled and prolonged release of fucose-presenting 
nanoparticles for long-term pancreatic cancer treatment is a 
noteworthy long-term goal.   
We report that the simple modification of PHPMA polymer 
chains with a single fucose unit enables the polymer to self-assemble, 
forming nanoparticles in aqueous solution. Such nanoparticles are 
stable at room temperature but undergo a morphological change 
upon heating to physiological temperature, which may be exploited 
to actuate therapeutic payload release. Unmodified PHPMA can 
form an injectable depot that undergoes a sol-gel transition at a 
temperature slightly above physiological temperature. 
Consequently, the depot, which is self-healing and can withhold 
guest molecules itself, may act as an injectable host for the 
controlled release of doxorubicin (Dox) from fucose-capped PHPMA 
nanoparticles at a localised site. 
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Experimental  
Materials and methods 
L(-)-Fucose 97 % was purchased from ACROS Organics. Chloroform 
(HPLC grade), dichloromethane (DCM) (HPLC grade) and acetone 
were obtained from VWR Chemicals. HPMA, Phosphate buffered 
saline tablet, N,N-dimethylformamide, 2,2’-azobis(2-methyl-
propionamidine) dihydrochloride (AAPH) granular 97 %, 4-cyano-4-
(phenylcarbonothioylthio)pentanoic acid N-succinimidyl ester 
(SCPDB), dialysis tubing benzoylated 2000 Da, deuterium oxide 99.9 
atom D% and acetic acid 99-100% were purchased from Sigma-
Aldrich. Triethylamine and tetrahydrofuran (THF, analytical grade) 
were obtained from Fisher Chemical. Sodium cyanoborohydride 
95%, and ethylenediamine 99% were purchased from Alfa Aesar. 
Sodium meta-periodate was obtained from Thermo Scientific. 4-
Cyano-4-((phenylcarbonothioyl)thiopentanoic acid, dimethyl 
sulfoxide and doxorubicin hydrochloride were purchased from 
Fluorochem. Dimethyl sulfoxide (99.80% D) was purchased from 
EURISO-TOP. 
     Chemical structures and functional groups were identified by 
Nuclear Magnetic Resonance spectroscopy (NMR, Bruker AVANCE III 
HD-400) and Attenuated Total Reflection (ATR-PLATINUM) Fourier 
Transform Infrared Spectroscopy (FTIR, BRUKER ALPHA). Scanning 
Electron Microscopy (SEM, FEI NanoSEM 450, elemental composition 
by energy-dispersive X-ray analysis) was employed to analyse size 
and topography of particle and particle surface. UV-vis spectroscopy 
(VARIAN 50 Probe UV-visible Spectrometer) was used to measure 
drug release from doxorubicin loaded polymer nanoparticles. 
Advanced Polymer Chromatography (APC) was employed to measure 
molecular weight of the synthesised polymers. APC was conducted 
on a Waters Acquity APC system using an Acquity column (Acquity 
APC TM 200 2.5 μm, 4.5 x 150 mm) calibrated against poly(methyl 
methacrylate) standards in THF. Dynamic Light Scattering (DLS) 
analysis was carried out in triplicate using a Malvern Zetasizer Nano 
ZSP series instrument with a 4 mW He-Ne laser at a wavelength at 
633 nm. An avalanche photodiode (APD) detector and DTS software 
were used. The light was scatted at 173 and collected by a back-
scatter-optic arrangement. Samples were equilibrated for 2 minutes 
prior to analysis at room temperature and at 37 C in disposable 
polystyrene cuvettes (1.5 mL to 3.0 mL). Glass transition 
temperatures were measured by Differential Scanning Calorimetry 
(DSC), using a TA Instruments DSC Q20 instrument with a heating 
rate of 5 C min-1 between 0-100 C and an inert gas flow of N2 at a 
rate of 50 mL.min-1. Rheology experiments were conducted using a 
rheometer (Anton Paar, MCR 302) with a 25 mm parallel plate. 
Frequency sweeps were recorded at 100-0.1 rad.s-1 with a constant 
amplitude (1%) at room temperature, using a 1.2 g PHPMA depot and 
a 1.9 mm gap. 
Fucose conjugation of ethylenediamine 
0.100 g of L(-)-Fucose was dissolved in 10.0 mL of deionised water. 
Then 0.391 g of sodium meta-periodate (mole ratio of fucose: 
sodium meta periodate = 1:3) was added to the fucose solution 
(colourless) and stirred overnight in the dark to activate the aldehyde 
group. 41.0 μL of ethylenediamine was added into the mixture which 
was then stirred overnight (mole ratio of fucose: ethylenediamine = 
1:1). 0.038 g of sodium cyanoborohydride was then added to the 
mixture which was stirred for 3 hours followed by underoing freeze 
drying for 48 hours (mole ratio of fucose: sodium cyanoborohydride 
= 1:1).  
SCPDB Conjugation to Amine-Bearing fucose 
0.118 g of fucose-amine and 0.213 g of SCPDB RAFT agent were 
dissolved in 5.0 mL of deionised water and 20.0 mL of acetone, 
respectively. The SCPDB RAFT agent solution was added dropwise 
into the fucose-amine solution with stirring followed by the addition 
of 3.0 mL of acetic acid. The mixture was stirred at 60 °C overnight. 
Following this, the solution underwent rotary evaporation at 60 °C to 
remove acetone and freeze-dried for 48 hours. The fucose-RAFT 
agent was washed multiple times with DCM, being recovered by 
centrifugation for 30 minutes at 4500 rpm, before finally being dried 
in a vacuum oven at room temperature overnight. 
HPMA Polymerisation from the fucose-RAFT agent 
0.052 g of fucose-RAFT agent was dissolved in 3.0 mL and 2.0 mL of 
acetone and deionised water. Then, 0.091 g of AAPH was dissolved 
in the mixture (mole ratio of fucose-RAFT agent: AAPH = 1:3). 1.608 
g of HPMA was added dropwise into the reaction which was stirred 
at 55 °C overnight (mole ratio of fucose-RAFT agent: HPMA = 1:100). 
The product underwent rotary evaporation at 50 °C for 20 minutes 
and the recovered product was freeze-dried overnight. Finally, 
fucose-PHPMA was washed multiple times with deionised water, 
being recovered by centrifugation for 30 minutes at 4500 rpm, 
before finally being freeze-dried for 48 hours. 
PHPMA synthesis: HPMA polymerisation from 4-Cyano-4-
((phenylcarbonothioyl)thiopentanoic acid 
0.020 g of 4-Cyano-4-((phenylcarbonothioyl)thiopentanoic acid RAFT 
agent was dissolved in 3.0 mL and 2.0 mL of acetone and deionised 
water, respectively. Then, 0.059 g of AAPH was dissolved into the 
mixture (mole ratio of RAFT agent:AAPH= 1:3). 1.025 g of HPMA was 
added dropwise into the reaction and stirred at 55 °C overnight (mole 
ratio of fucose-RAFT agent:HPMA= 1:100). The product was rotary 
evaporated at 50 °C for 20 minutes and freeze dried for 48 hours. 
Finally, PHPMA was washed with deionised water, centrifugation for 
30 minutes at 4500 rpm and freeze dried for 48 hours. 
PHPMA gel synthesis: HPMA Polymerisation from 4-Cyano-4-
((phenylcarbonothioyl)thiopentanoic acid 
As a representative procedure to produce PHPMA200: 0.020 g of 4-
Cyano-4-((phenylcarbonothioyl)thiopentanoic acid RAFT agent was 
dissolved in 3.0 mL and 2.0 mL of acetone and deionised water, 
respectively. Then, 0.059 g of AAPH was dissolved into the mixture 
(mole ratio of RAFT agent: AAPH= 1:3). 2.050 g of HPMA was added 
dropwise into the reaction, which was stirred at 55 °C overnight 
(mole ratio of fucose-RAFT agent: HPMA = 1:200). 
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Results and discussion 
The overall route to fucose-capped PHPMA nanoparticles that are 
able to withhold, and gradually release Dox is presented in Fig. 1, and 
detailed reaction schemes provided in Schemes S1-S2. Fucose was 
successfully oxidised by sodium meta-periodate, as confirmed by the 
proton corresponding to the aldehyde group being present in the 1H 
NMR spectrum (Fig. S1). Fucose-amine was produced by sequential 
reaction with ethylene diamine and sodium cyanoborohydride, and 
the structure confirmed by 13C NMR (Fig. S3). The peaks present in 
the region 40-55 ppm are assigned to the conjugated diamine. RAFT 
agent conjugation to fucose-amine, to enable RAFT polymerisation 
to occur from the fucose-amine initiator, was confirmed by the peaks 
in the aromatic region of Fig. S5, which remained after thorough 
washing with DCM. Different chain lengths (20, 40, 60, 80 and 100 
repeat units) of fucose-PHPMA were synthesised to ascertain the 
optimal polymer for stable nanoparticle formation. The average 
molecular weight values of fucose-PHPMA with 20, 40, 60, 80 and 
100 repeat units were assessed by 1H NMR spectroscopy using the 
proton environments of the RAFT agent aromatic group and peaks f, 
g, h, e, d and i to confirm that the desired polymers were produced 
(Figs. S6-S10). APC was used to further evaluate polymer molecular 
weight (Table S1).  
The products from each step of the overall reaction (Scheme S1) 
were analysed by FTIR spectroscopy. The aldehyde group of opened 
fucose (Fig. S17 black) confirms fucose oxidation by sodium meta-
periodate. Peaks corresponding to C=S, C-S and aromatic groups can 
be found in the FTIR spectra of the fucose-RAFT agent, and fucose-
PHPMA, confirming successful synthesis of activated fucose and the 
desired final product, respectively (Fig. S17 and Fig. S18). 
Additionally, a strong and broad peak corresponding to the alcohol 
group is present in the fucose-PHPMA FTIR spectrum further 
confirming HPMA polymerisation from the fucose-RAFT agent (Fig. 
S17). This route to product, in which the RAFT agent is covalently 
conjugated to fucose, ensures that each PHPMA chain possesses a 
desired terminal fucose unit.  
Nanoparticles were produced from the various fucose-PHPMA  
                                                                                                                                             
batches by coacervation. Nanoparticle size increased with polymer 
chain length when Dox was absent from the nanoparticles, and also 
when Dox was loaded into the nanoparticles (Tables 1 and 2). At 
room temperature, the particle sizes of blank and Dox-loaded 
nanoparticles were comparable both in terms of dimensions and PDI 
values. In all instances, the PDI values were less than 0.3, confirming 
a stable dispersion formed. Conversely, PHPMA of the same number 
of repeat units, but lacking fucose, did not form stable nanoparticles 
 
Fig. 1 Reaction outline for the creation of fucose-PHPMA100 nanoparticles that are capable of encapsulating, and releasing Dox at 
physiological temperature. 
Table 1. Nanoparticle size and PDI values for nanoparticles formed 
from fucose-PHPMA (DMF:H2O, 1:1 volume ratio), maintained at 
room temperature. The nanoparticles were measured both when 
vacant and loaded with Dox.  
Polymer Size (nm) PDI 
Fucose-PHPMA20 93 ±5 0.170 
Fucose-PHPMA40 106 ±6 0.205 
Fucose-PHPMA60 121 ±1 0.169 
Fucose-PHPMA80 163 ±6 0.165 
Fucose-PHPMA100 217 ±3 0.151 
Fucose-PHPMA20 (Dox)± 91 ±2 0.209 
Fucose-PHPMA40 (Dox) ± 108 ±4 0.218 
Fucose-PHPMA60 (Dox) ± 122 ±1 0.186 
Fucose-PHPMA80 (Dox) ± 165 ±2 0.217 
Fucose-PHPMA100 (Dox) ± 219 ±2 0.181 
± Denotes Dox-loaded nanoparticles. 
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(Table S2), emphasising the necessity for fucose conjugation to 
PHMPA for stable nanoparticle assembly. Fucose-PHPMA100 with and 
without Dox-loading were shown as spherical nanoparticles by SEM 
analysis (Fig. 2 (a) and (b), respectively). 
To assess the thermoresponse of fucose-PHPMA nanoparticles, 
their dimensions were assessed by DLS at 37 °C. The particle size 
of all types of fucose-PHPMA nanoparticles decreased 
significantly at 37 °C, signifying a thermo-responsive behaviour 
(Table 2). PDI values of the particles at 37 °C were slightly higher 
than those at room temperature, however all samples had PDI 
values less than 0.3, confirming their stability against aggregation. 
Significantly smaller artefacts were present in the SEM images of 
Dox-loaded fucose-PHPMA100 nanoparticles at 37 °C that are 
assigned to released Dox (Fig. S20 (d)). 
0.033 mg (11%), 0.093 mg (31%), 0.158 mg (53%), 0.221 mg (74%) 
and 0.245 mg (82%) of Dox was then loaded into fucose-PHPMA20, 
fucose-PHPMA40, fucose-PHPMA60, fucose-PHPMA80 and fucose-
PHPMA100 nanoparticles in PBS buffer solution, respectively. The 
extent of Dox release from each configuration of fucose-PHPMA 
nanoparticles was assessed at room temperature and at 37 °C (Fig. 
3). Negligible release of Dox after 168 hours (≈ 1.6% for all 
nanoparticle samples) from the series of particles demonstrated that 
Dox can largely be held within all formed nanoparticles at room 
temperature (Fig. 3 (a)). Particles created from fucose-PHPMA20 
revealed the most rapid release of Dox at 37 °C, with complete 
release occurring after 29 hours (Fig. 3 (b)). Restricted Dox release 
corresponded with greater HPMA content within the nanoparticles, 
enabling the release rate to be tuned by polymer composition. The 
extent of Dox release was determined to be 100%, 66%, 46% and 31% 
for fucose-PHPMA40, fucose-PHPMA60, fucose-PHPMA80 and fucose-
PHPMA100 nanoparticles, respectively, after 168 hours (Fig. 3 (b)). 
Since fucose-PHPMA100 nanoparticles (with and without Dox) 
possessed the lowest PDI values, this material was taken forward for 
further analysis. The initial release studies revealed that 13 % of Dox 
was released from fucose-PHPMA100 particles after 24 hours at 37 °C, 
the lowest release of all nanoparticle samples (Fig. 3 (b)). Detailed 
release studies were then conducted in order to investigate the 
 
Fig. 2 SEM images of fucose-PHPMA100 nanoparticles (a) and Dox-
loaded fucose-PHPMA100 nanoparticles (b). 
 
Fig. 3 Dox release from fucose-PHPMA20, fucose-PHPMA40, fucose-
PHPMA60, fucose-PHPMA80 and fucose-PHPMA100 nanoparticles (a) 
at room temperature PBS buffer solution and (b) at 37 °C in PBS 
buffer solution. 
 
Table 2. Nanoparticle size and PDI values obtained for nanoparticles 
formed from fucose-PHPMA, maintained in aqueous solution at 37 
°C. The nanoparticles were measured both when vacant and loaded 
with Dox. 
Polymer Size (nm) PDI 
Fucose-PHPMA20 12 ±0.2 0.203 
Fucose-PHPMA40 16 ±2.5 0.215 
Fucose-PHPMA60 19 ±1.2 0.217 
Fucose-PHPMA80 22 ±1.3 0.218 
Fucose-PHPMA100 32 ±3.3 0.232 
Fucose-PHPMA20 (Dox)± 11 ±1.6 0.238 
Fucose-PHPMA40 (Dox)± 16 ±0.8 0.251 
Fucose-PHPMA60 (Dox)± 19 ±1.3 0.256 
Fucose-PHPMA80 (Dox)± 22 ±1.5 0.233 
Fucose-PHPMA100 (Dox)± 32 ±1.0 0.201 
± Denotes Dox-loaded nanoparticles. 
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specific temperature that lead to complete Dox release, with studies 
conducted that measured Dox release at various temperatures. To 
begin with, the Dox release study ran over a temperature range from 
22 °C to 50 °C and the solution temperature was increased by 1 °C 
every 15 minutes (Fig. 4 (a)). Extensive Dox release occurred between 
39 °C (19%) and 46 °C (47%) (Fig. 4 (a)). The temperature range of 
greatest Dox release was then narrowed to between 35 °C and 46 °C, 
by increasing the solution temperature by 1 °C every 40 minutes. 
Extensive Dox release (19.2 %, 0.041 mg) occurred between 41 °C 
and 42 °C (Fig. 4 (b)), demonstrating the potential of the reported 
materials to release Dox more extensively under moderate heating. 
Further Dox release studies were carried out to determine the time 
required for complete Dox release to occur at 41 °C. 22 % (0.048 mg) 
of Dox was released in the first hour (Fig. 4 (c)), with continuous 
release culminating in 51 % (0.126 mg), 74 % (0.183 mg) and 90 % 
(0.221 mg) Dox release after 24 hours, 48 hours and 72 hours, 
respectively (Fig. 4 (d)). Dox release from the fucose-PHPMA100 
nanoparticles reached 100 % (0.245 mg) after 96 hours.  
Next, a thermoresponsive PHPMA depot was created that may 
act as an injectable delivery vehicle, and host, for Dox-loaded fucose-  
 
 
Fig. 4 (a) Dox release from fucose-PHPMA100 nanoparticles into solution increasing in temperature from 22 °C to 50 °C at a rate of 1 °C every 
15 minutes. (b) Dox release from fucose-PHPMA100 nanoparticles into solution increasing in temperature from 35 °C to 46 °C at a rate of 1 
°C every 40 minutes (c) Dox release from fucose-PHPMA100 nanoparticles, monitored every five minutes at 41 °C. (d) Dox release from 
nanoparticles maintained at 41 °C over 7 days. 
 
Fig. 5 The percentage of Dox released from fucose-PHPMA100 
nanoparticles loaded in PHPMA200 depot maintained in PBS buffer 
solution at room temperature, and at 37 °C 
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Fig. 6 0.002 mg mL-1 of rhodamine b was used to partially colour PHPMA200. a) Stretching PHPMA200; b-e) Demonstration of PHPMA200 self-
healing at 25 °C for one hour; f-i) Demonstration of PHPMA200 self-healing at 25 °C for one hour in PBS buffer solution; j-m) Demonstration 
of PHPMA200 self-healing at 37 °C for one hour; n-q) Demonstration of PHPMA200 self-healing at 37 °C for one hour in PBS buffer solution.  
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PHPMA100 nanoparticles that enables localised drug release (Fig. 
S23). PHPMA80 and PHPMA200 depots were synthesised by RAFT 
polymerisation (Scheme S2). PHPMA depot formation occurred upon 
polymer/DMSO solution being added to PBS buffer solution. The 
glass transition temperature of the depots was greater with 
increased polymer chain length (Fig. S24), and the water content of 
the two depots were 87.1 % (PHPMA80) and 82.5 % (PHPMA200), by 
mass (Table S3). The loss modulus of PHPMA200 depot formed in PBS 
buffer solution was constant across the 0.1-100 frequency range 
indicating that the material was stable and inelastic (Fig. S26). 
PHPMA80 and PHPMA200 depots were then created in the presence 
of Dox fucose-PHPMA100 nanoparticles (Fig. S27). Due to the 
enhanced thermal and mechanical stability of the PHPMA200 depot, 
Dox release from nanoparticles embedded within this material was 
studied at room temperature and at 37 °C (Fig. 5). Dox release 
increased up to 168 hours in solution maintained at 37 °C, before 
43.9 % (0.011 mg) Dox release was recorded after 288 hours. Only a 
negligible amount of Dox release (2.3 %, 0.0006 mg) occurred at 
room temperature after 288 hours. The polymer nanoparticles are 
unable to penetrate the PHPMA depot, ensuring that they remain at 
the injection site following their administration.  
Further studies revealed that the PHPMA200 depot possesses self-
healing properties. Two batches of the PHPMA200 material were 
produced; one containing aqueous rhodamine b solution 
incorporated and the other containing water only, for illustrative 
purposes. The PHPMA200 material can be stretched to 24.0 cm 
unevenly, which corresponds to 1200% elongation (Fig. 6a). 
Rhodamine b-containing material was placed in contact with blank 
PHPMA200 material, in the presence and absence of PBS buffer 
solution at 25 °C and at 37 °C (Fig. 6, c, g, k and o). Over 1 hour, the 
two independent materials connected to reveal the self-healing 
properties of the PHPMA200 depot, indicating its potential suitability 
to be maintained for extended periods, and self-heal if damaged, in 
vivo (Fig. 6, e, i, m and q).  
The PHPMA200 depot could also withhold rhodamine b in the 
absence of nanoparticles and be manipulated to form distinct and 
stable forms in PBS buffer solution. Rhodamine b-containing material 
could be formed upon injection onto a glass sheet as a viscous liquid 
(Fig. 7a). Upon the addition of PBS buffer solution, a depot formed 
that maintained both the loaded rhodamine b, and a defined 
structure. These materials could be rearranged and floated on the 
buffer solution, with the fusion of letters D and E occurring as further 
evidence of a self-healing material (Fig. 7c). The material dimensions 
and rhodamine b payload were both retained in PBS buffer solution, 
before the shapes were retrieved from solution and placed on a 
different glass sheet (Fig. 7d). The letters could be removed intact 
from solution and placed on a new glass sheet. 
Conclusions 
Thermally-responsive fucose-modified PHPMA nanoparticles were 
synthesised by RAFT polymerisation. A single fucose group per 
polymer chain was sufficient to instigate polymer self-assembly to 
yield nanoparticles in aqueous solution. Spherical fucose-PHPMA 
nanoparticles that contained or lacked Dox were very stable at room 
temperature and at 37 °C, as determined by DLS and SEM analysis. 
Dox loading into the nanoparticles was achieved by coacervation; 
negligible Dox release from the nanoparticles occurred at room 
temperature, whilst extensive release occurred upon the solution 
temperature increasing to 41 °C. An injectable PHPMA200 depot was 
synthesised by RAFT polymerisation as a delivery vehicle for fucose-
PHPMA100 nanoparticles. This material possessed self-healing 
properties in PBS buffer solution and offers great promise to enable 
nanoparticle localisation at a target site for the prolonged release of 
anticancer therapeutics. 
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